Albert, Marie-Christine
Uranga-Murillo, Iratxe
Arias, Maykel
De Miguel, Diego http://orcid.org/0000-0002-8486-8514
Peña, Natacha
Montinaro, Antonella http://orcid.org/0000-0002-2289-9374
Varanda, Ana Beatriz
Theobald, Sebastian J.
Areso, Itziar
Saggau, Julia
Koch, Manuel http://orcid.org/0000-0002-2962-7814
Liccardi, Gianmaria http://orcid.org/0000-0002-2662-1281
Peltzer, Nieves http://orcid.org/0000-0002-4134-5852
Rybniker, Jan http://orcid.org/0000-0001-8351-2690
Hurtado-Guerrero, Ramón http://orcid.org/0000-0002-3122-9401
Merino, Pedro
Monzón, Marta
Badiola, Juan J.
Reindl-Schwaighofer, Roman
Sanz-Pamplona, Rebeca
Cebollada-Solanas, Alberto
Megyesfalvi, Zsolt
Dome, Balazs
Secrier, Maria
Hartmann, Boris
Bergmann, Michael http://orcid.org/0000-0001-8529-1166
Pardo, Julián http://orcid.org/0000-0003-0154-0730
Walczak, Henning http://orcid.org/0000-0002-6312-4591
Funding for this research was provided by:
Alexander von Humboldt-Stiftung (214342/Z/18/Z)
Deutsche Forschungsgemeinschaft (SFB1399, Project C06, SFB1530-455784452, Project A03, SFB1403–414786233)
Ministry of Economy and Competitiveness | Agencia Estatal de Investigación (PID2019-105451GB-I00, PID2020-113963RBI00)
Article History
Received: 15 January 2024
Revised: 4 March 2024
Accepted: 8 March 2024
First Online: 21 March 2024
Competing interests
: HW is co-founder of Apogenix, a biotech company that develops asunercept. The authors declare no other competing interests.